Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ARS Pharmaceuticals, Inc. - Common Stock
(NQ:
SPRY
)
7.425
-0.515 (-6.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ARS Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
September 19, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
September 08, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
August 28, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Outlook For ARS Pharmaceuticals
↗
August 12, 2025
Via
Benzinga
ARS Pharmaceuticals's Earnings: A Preview
↗
May 13, 2025
Via
Benzinga
ARS Pharma Sales Jump 3,040% in Q2
↗
August 13, 2025
Via
The Motley Fool
ARS Pharmaceuticals Inc (NASDAQ:SPRY) Reports Mixed Q2 2025 Earnings with Revenue Beat but Investor Caution Persists
↗
August 13, 2025
ARS Pharma Q2 2025 results: $15.7M revenue beats estimates, but stock dips amid high SG&A costs. neffy gains traction with 93% U.S. coverage and global expansion underway.
Via
Chartmill
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
August 13, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
August 04, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For August 13, 2025
↗
August 13, 2025
Via
Benzinga
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
July 18, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs
↗
June 12, 2025
Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said.
Via
Benzinga
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
May 27, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
May 14, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
May 07, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
May 05, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For May 14, 2025
↗
May 14, 2025
Via
Benzinga
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
May 02, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
March 20, 2025
Via
Benzinga
Which stocks are gapping on Thursday?
↗
March 20, 2025
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.
↗
March 20, 2025
The company is known for its first-of-a-kind drug, a nasal treatment for emergency allergic reactions.
Via
Investor's Business Daily
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
↗
March 20, 2025
Via
Benzinga
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 20, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment
↗
March 06, 2025
FDA approves ARS Pharma's Neffy 1 mg, the first nasal epinephrine spray for children with severe allergies, offering a needle-free alternative to autoinjectors.
Via
Benzinga
Earnings Scheduled For March 20, 2025
↗
March 20, 2025
Via
Benzinga
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
March 05, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
March 03, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
February 20, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
February 18, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
February 05, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
